Skip to main content

Table 1 Characterization of Afa/LPN and peptide-modified LPNs

From: Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model

Formulations

Particle size (nm)

PdIa

Zeta potential (mV)

EE%b

LPN

145.26 ± 2.48

0.20 ± 0.04

− 15.28 ± 2.16

Afa/LPN

168.61 ± 4.10

0.22 ± 0.03

− 13.83 ± 0.49

87.52 ± 1.72

Afa/LPN-FD7

166.12 ± 8.91

0.21 ± 0.02

− 10.74 ± 1.42

87.33 ± 1.54

Afa/LPN-CCD

150.18 ± 0.31

0.23 ± 0.03

−  25.32 ± 1.50

86.83 ± 1.62

  1. aPdI polydispersity index
  2. bEE% encapsulation efficiency